Nuclear Medicine/Radiopharmaceuticals Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Nuclear Medicine/Radiopharmaceuticals Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Nuclear Medicine/Radiopharmaceuticals Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxxxxxx
North Americaxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

The diagnostic product segment, which accounted for XX% of the market share in 2023, is largely driven by advanced technologies like SPECT and PET. With 40 million nuclear medicine procedures performed annually, the demand for radioisotopes is increasing by around 5% annually. Technological advancements and a wide range of radiotracers contribute to the market growth. The therapeutic segment is divided into alpha emitters, beta emitters, and brachytherapy. The U.S. FDA approved and granted a breakthrough designation to diffuse alpha-emitter Radiation Therapy (DaRT) for recurrent glioblastoma multiforme (GBM) patients. Radium (Ra-223) is the most widely used alpha emitter in therapeutics. The development of potential radioisotopes like Terbium (Tb-149), Bismuth (Bi-212), and Actinium (Ac-225) is expected to further boost market growth.

Diagnostic Products Nuclear Medicine/Radiopharmaceuticals Market Analysis
XX
Diagnostic Products Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Therapeutic Products Nuclear Medicine/Radiopharmaceuticals Market Analysis
XX
Therapeutic Products Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive landscape - Nuclear Medicine & Radiopharmaceuticals market

Nuclear medicine uses radioactive materials to diagnose and treat illnesses, using imaging to capture radiation released from the body. This method focuses on organ and tissue function rather than architecture, allowing for early disease detection and effective treatment. The radiopharmaceuticals market is growing due to innovation and advanced technologies, with Novartis' FDA approval for Pluvicto production in April 2023 being a significant milestone. Leading players are conducting M&As to expand services and access new technologies. Regulatory scrutiny is increasing, with Title 21 governing radiopharmaceuticals in the U.S., Part 315 & Part 361, and the Nuclear Regulatory Commission in 37 states. The Center for Devices and Radiology Health (CDRH) and the FDA Modernization Act of 1997 also regulate radiopharmaceuticals. Several market players, including Cardinal Health, Advanced Accelerator Applications (Novartis AG), Bayer AG, GE Healthcare, Curium, and Jubilant Pharmova Limited, hold around 60% of the global market. They focus on strategies such as new product launches, acquisitions, mergers, and continuous R&D, resulting in strong regulatory approvals.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
GE Healthcare••• ••• ••• •••
Jubilant Life Sciences Ltd••• ••• ••• •••
Nordion (Canada)••• ••• ••• •••
Inc.••• ••• ••• •••
Bracco Imaging S.P.A••• ••• ••• •••
The Institute for radioelements (IRE)••• ••• ••• •••
NTP Radioisotopes SOC Ltd.••• ••• ••• •••
The Australian Nuclear Science and Technology Organization••• ••• ••• •••
Eczacıbaşı-Monrol••• ••• ••• •••
Lantheus Medical Imaging••• ••• ••• •••
Inc••• ••• ••• •••
Eckert & Ziegler••• ••• ••• •••
Mallinckrodt••• ••• ••• •••
Cardinal Health••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

  • The global Nuclear Medicine & Radiopharmaceuticals market will expand significantly by xx% CAGR between 2024 and 2031.

  • The demand for Diagnostic Products is rising in the global Nuclear Medicine & Radiopharmaceuticals market.

  • The demand for the Oncology segment is rising in the global Nuclear Medicine & Radiopharmaceuticals market.

  • The demand for the Hospitals & Clinics segment is rising in the global Nuclear Medicine & Radiopharmaceuticals market.

  • North America region will continue to lead, as dominating region and highest compound annual growth rate in the forecast year 2024 to 2031.

Introduction Nuclear Medicine & Radiopharmaceuticals market

Radioactive materials are used in the diagnosis and treatment of illnesses in the medical profession known as nuclear medicine. Nuclear imaging captures radiation released from within the body, as opposed to traditional radiography, which records radiation passed through the body from external sources such as X-ray machines. Nuclear medicine scans are physiological imaging modalities because they focus on the function of organs and tissues rather than their architecture. Small quantities of radioactive material, a specialized camera, and a computer are used in nuclear medicine imaging to provide photographs of the interior of the body. This makes it possible to diagnose a variety of malignancies, cardiac problems, neurological, gastrointestinal, and endocrine diseases, among other illnesses. Because nuclear medicine scans capture molecular activity within the body, they can detect disease in its early stages, when it may be treated most effectively. The radiopharmaceuticals market is experiencing significant growth due to innovation and advanced technologies. Novartis' FDA approval for Pluvicto production in April 2023 is a significant milestone in the market. Leading players are also conducting M&As to expand services, access new technologies, and consolidate in the rapidly growing market. Regulatory scrutiny is increasing, with Title 21 from the Code of Federal Regulations governing radiopharmaceuticals in the U.S., Part 315 & Part 361, and the Nuclear Regulatory Commission (NRC) in 37 states. The Center for Devices and Radiology Health (CDRH) and the FDA Modernization Act of 1997 also regulate radiopharmaceuticals. Although radiopharmaceutical methods are more accurate than traditional methods, the higher price increases the risk of using substitute products. The threat of substitution is expected to be moderate during the forecast period.

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Nuclear Medicine/Radiopharmaceuticals Market Analysis is witnessing significant growth in the near future.

In 2023, the Diagnostic Products segment accounted for a notable share of the Nuclear Medicine/Radiopharmaceuticals Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

The Nuclear Medicine & Radiopharmaceuticals Market size will grow at approximately a CAGR of XX% during the forecast.
Some of the top industry players in the Nuclear Medicine & Radiopharmaceuticals market are GE Healthcare, Jubilant Life Sciences Ltd, Nordion (Canada), Inc., Bracco Imaging S.P.A, The Institute for Radioelements (IRE), NTP Radioisotopes SOC Ltd., The Australian Nuclear Science and Technology Organization, Eczac?ba??-Monrol, Lantheus Medical Imaging, Inc, Eckert & Ziegler, Mallinckrodt, and Cardinal Health among others.
In the Nuclear Medicine & Radiopharmaceuticals Market, North America has established itself as the market leader with a significant market share.
The Nuclear Medicine & Radiopharmaceuticals market has seen the most substantial growth rate in Asia Pacific.
The Global Nuclear Medicine & Radiopharmaceuticals market report is segmented as follows – type, application, end-user, and region.

★ Reviews

Rate this report

Nuclear Medicine/Radiopharmaceuticals Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Product typeDiagnostic Products, Therapeutic Products
ApplicationCardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumour, Others
End-use Hospitals & Clinics, Diagnostic Centres, Others
List of CompetitorsGE Healthcare, Jubilant Life Sciences Ltd, Nordion (Canada), Inc., Bracco Imaging S.P.A, The Institute for radioelements (IRE), NTP Radioisotopes SOC Ltd., The Australian Nuclear Science and Technology Organization, Eczacıbaşı-Monrol, Lantheus Medical Imaging, Inc, Eckert & Ziegler, Mallinckrodt, Cardinal Health

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Nuclear Medicine/Radiopharmaceuticals Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 GE Healthcare
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Jubilant Life Sciences Ltd
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Nordion (Canada)
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Inc.
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 Financials (Subject to data availability)
        • 1.2.4.4 R&D Investment (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Bracco Imaging S.P.A
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 Financials (Subject to data availability)
        • 1.2.5.4 R&D Investment (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 The Institute for radioelements (IRE)
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 Financials (Subject to data availability)
        • 1.2.6.4 R&D Investment (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 NTP Radioisotopes SOC Ltd.
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 Financials (Subject to data availability)
        • 1.2.7.4 R&D Investment (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 The Australian Nuclear Science and Technology Organization
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 Financials (Subject to data availability)
        • 1.2.8.4 R&D Investment (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Eczacıbaşı-Monrol
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 Financials (Subject to data availability)
        • 1.2.9.4 R&D Investment (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Lantheus Medical Imaging
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 Financials (Subject to data availability)
        • 1.2.10.4 R&D Investment (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Inc
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 Financials (Subject to data availability)
        • 1.2.11.4 R&D Investment (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis
      • 1.2.12 Eckert & Ziegler
        • 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.12.2 Business Overview
        • 1.2.12.3 Financials (Subject to data availability)
        • 1.2.12.4 R&D Investment (Subject to data availability)
        • 1.2.12.5 Product Types Specification
        • 1.2.12.6 Business Strategy
        • 1.2.12.7 Recent Developments
        • 1.2.12.8 Management Change
        • 1.2.12.9 S.W.O.T Analysis
      • 1.2.13 Mallinckrodt
        • 1.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.13.2 Business Overview
        • 1.2.13.3 Financials (Subject to data availability)
        • 1.2.13.4 R&D Investment (Subject to data availability)
        • 1.2.13.5 Product Types Specification
        • 1.2.13.6 Business Strategy
        • 1.2.13.7 Recent Developments
        • 1.2.13.8 Management Change
        • 1.2.13.9 S.W.O.T Analysis
      • 1.2.14 Cardinal Health
        • 1.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.14.2 Business Overview
        • 1.2.14.3 Financials (Subject to data availability)
        • 1.2.14.4 R&D Investment (Subject to data availability)
        • 1.2.14.5 Product Types Specification
        • 1.2.14.6 Business Strategy
        • 1.2.14.7 Recent Developments
        • 1.2.14.8 Management Change
        • 1.2.14.9 S.W.O.T Analysis

  • Chapter 2. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis

    • 2.1 Global Nuclear Medicine/Radiopharmaceuticals Market Analysis
    • 2.2 Global Nuclear Medicine/Radiopharmaceuticals Market Analysis by Region
    • 2.3 Global Nuclear Medicine/Radiopharmaceuticals Market Analysis by Product type
    • 2.4 Global Nuclear Medicine/Radiopharmaceuticals Market Analysis by Application
    • 2.5 Global Nuclear Medicine/Radiopharmaceuticals Market Analysis by End-use
    • 2.6 Global Nuclear Medicine/Radiopharmaceuticals Market Analysis by Key Players

  • Chapter 3. North America Nuclear Medicine/Radiopharmaceuticals Market Analysis

    • 3.1 North America Nuclear Medicine/Radiopharmaceuticals Market Analysis
    • 3.2 North America Nuclear Medicine/Radiopharmaceuticals Market Analysis by Country
    • 3.3 North America Nuclear Medicine/Radiopharmaceuticals Market Analysis by Product type
    • 3.4 North America Nuclear Medicine/Radiopharmaceuticals Market Analysis by Application
    • 3.5 North America Nuclear Medicine/Radiopharmaceuticals Market Analysis by End-use
    • 3.6 North America Nuclear Medicine/Radiopharmaceuticals Market Analysis by Key Players

  • Chapter 4. Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis

    • 4.1 Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis
    • 4.2 Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis by Country
    • 4.3 Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis by Product type
    • 4.4 Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis by Application
    • 4.5 Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis by End-use
    • 4.6 Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis by Key Players

  • Chapter 5. Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis

    • 5.1 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis
    • 5.2 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis by Country
    • 5.3 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis by Product type
    • 5.4 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis by Application
    • 5.5 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis by End-use
    • 5.6 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis by Key Players

  • Chapter 6. South America Nuclear Medicine/Radiopharmaceuticals Market Analysis

    • 6.1 South America Nuclear Medicine/Radiopharmaceuticals Market Analysis
    • 6.2 South America Nuclear Medicine/Radiopharmaceuticals Market Analysis by Country
    • 6.3 South America Nuclear Medicine/Radiopharmaceuticals Market Analysis by Product type
    • 6.4 South America Nuclear Medicine/Radiopharmaceuticals Market Analysis by Application
    • 6.5 South America Nuclear Medicine/Radiopharmaceuticals Market Analysis by End-use
    • 6.6 South America Nuclear Medicine/Radiopharmaceuticals Market Analysis by Key Players

  • Chapter 7. Middle East Nuclear Medicine/Radiopharmaceuticals Market Analysis

    • 7.1 Middle East Nuclear Medicine/Radiopharmaceuticals Market Analysis
    • 7.2 Middle East Nuclear Medicine/Radiopharmaceuticals Market Analysis by Country
    • 7.3 Middle East Nuclear Medicine/Radiopharmaceuticals Market Analysis by Product type
    • 7.4 Middle East Nuclear Medicine/Radiopharmaceuticals Market Analysis by Application
    • 7.5 Middle East Nuclear Medicine/Radiopharmaceuticals Market Analysis by End-use
    • 7.6 Middle East Nuclear Medicine/Radiopharmaceuticals Market Analysis by Key Players

  • Chapter 8. Africa Nuclear Medicine/Radiopharmaceuticals Market Analysis

    • 8.1 Africa Nuclear Medicine/Radiopharmaceuticals Market Analysis
    • 8.2 Africa Nuclear Medicine/Radiopharmaceuticals Market Analysis by Country
    • 8.3 Africa Nuclear Medicine/Radiopharmaceuticals Market Analysis by Product type
    • 8.4 Africa Nuclear Medicine/Radiopharmaceuticals Market Analysis by Application
    • 8.5 Africa Nuclear Medicine/Radiopharmaceuticals Market Analysis by End-use
    • 8.6 Africa Nuclear Medicine/Radiopharmaceuticals Market Analysis by Key Players

  • Chapter 9. Product type Analysis

    • 9.1 Diagnostic Products
      • 9.1.1 Global Diagnostic Products Market
      • 9.1.2 Global Diagnostic Products Market by Region
    • 9.2 Therapeutic Products
      • 9.2.1 Global Therapeutic Products Market
      • 9.2.2 Global Therapeutic Products Market by Region

  • Chapter 10. Application Analysis

    • 10.1 Cardiology
      • 10.1.1 Global Cardiology Market
      • 10.1.2 Global Cardiology Market by Region
    • 10.2 Neurology
      • 10.2.1 Global Neurology Market
      • 10.2.2 Global Neurology Market by Region
    • 10.3 Oncology
      • 10.3.1 Global Oncology Market
      • 10.3.2 Global Oncology Market by Region
    • 10.4 Thyroid
      • 10.4.1 Global Thyroid Market
      • 10.4.2 Global Thyroid Market by Region
    • 10.5 Lymphoma
      • 10.5.1 Global Lymphoma Market
      • 10.5.2 Global Lymphoma Market by Region
    • 10.6 Bone Metastasis
      • 10.6.1 Global Bone Metastasis Market
      • 10.6.2 Global Bone Metastasis Market by Region
    • 10.7 Endocrine Tumour
      • 10.7.1 Global Endocrine Tumour Market
      • 10.7.2 Global Endocrine Tumour Market by Region
    • 10.8 Others
      • 10.8.1 Global Others Market
      • 10.8.2 Global Others Market by Region

  • Chapter 11. End-use Analysis

    • 11.1 Hospitals & Clinics
      • 11.1.1 Global Hospitals & Clinics Market
      • 11.1.2 Global Hospitals & Clinics Market by Region
    • 11.2 Diagnostic Centres
      • 11.2.1 Global Diagnostic Centres Market
      • 11.2.2 Global Diagnostic Centres Market by Region
    • 11.3 Others
      • 11.3.1 Global Others Market
      • 11.3.2 Global Others Market by Region

  • Chapter 12. Qualitative Analysis (Subject to Data Availability)

    • 12.1 Market Drivers
    • 12.2 Market Restraints
    • 12.3 Market Trends
    • 12.4 Market Opportunity
    • 12.5 Technological Road Map (Subject to Data Availability)
    • 12.6 Product Life Cycle (Subject to Data Availability)
    • 12.7 Customer and Buyer Behavior Analysis
      • 12.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 12.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 12.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 12.7.4 Pricing, Affordability & Value Perception Analysis
      • 12.7.5 Customer Segmentation & Demand Pattern Analysis
    • 12.8 PESTEL Analysis
      • 12.8.1 Political Factors
      • 12.8.2 Economic Factors
      • 12.8.3 Social Factors
      • 12.8.4 Technological Factors
      • 12.8.5 Legal Factors
      • 12.8.6 Environmental Factors
    • 12.9 Industrial Chain Analysis (Subject to Data Availability)
      • 12.9.1 Industry Chain Analysis
      • 12.9.2 Manufacturing Cost Analysis
      • 12.9.3 Supply Side Analysis
        • 12.9.3.1 Raw Material Analysis
        • 12.9.3.2 Raw Material Procurement Analysis
        • 12.9.3.3 Raw Material Price Trend Analysis
    • 12.10 Porter’s Five Forces Analysis
      • 12.10.1 Bargaining Power of Suppliers
      • 12.10.2 Bargaining Power of Buyers
      • 12.10.3 Threat of New Entrants
      • 12.10.4 Threat of Substitutes
      • 12.10.5 Degree of Competition
    • 12.11 Patent Analysis (Subject to Data Availability)
    • 12.12 ESG Analysis
    • 12.13 Geopolitical Outlook
      • 12.13.1 Global Power Realignment & Strategic Alliances
      • 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 12.13.3 International Trade Relations & Market Access Environment
      • 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 12.13.6 Technology Sovereignty & Digital Geopolitics
      • 12.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 12.14 AI & Market Transformation
      • 12.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 12.14.2 AI-Driven Transformation of Industry Value Chain
      • 12.14.3 Evolution of Business Models & Revenue Streams
      • 12.14.4 AI-Driven Product, Service & Innovation Transformation
      • 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 13. TOP 10 Country Analysis

    • 13.1 Country 1
    • 13.2 Country 2
    • 13.3 Country 3
    • 13.4 Country 4
    • 13.5 Country 5
    • 13.6 Country 6
    • 13.7 Country 7
    • 13.8 Country 8
    • 13.9 Country 9
    • 13.10 Country 10

  • Chapter 14. Research Findings

    • 14.1 Key Takeaways
    • 14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

  • Chapter 15. Research Methodology and Sources

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Nuclear Medicine/Radiopharmaceuticals Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 14+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Nuclear Medicine/Radiopharmaceuticals Market

For example,
GE Healthcare and NorthStar Medical Radioisotopes, LLC announced in August 2021 that they had reached an exclusive deal to produce and sell iodine-123 (I-123) capsules in the United States. The device will boost GE Healthcare's market presence and aid in diversifying its product line.

Source  (https://www.northstarnm.com/northstar-medical-radioisotopes-and-ge-healthcare-sign-exclusive-u-s-manufacturing-and-distribution-agreement/) 

For example,
For example, Noria Therapeutics Inc. and PSMA Therapeutics Inc. were acquired by Bayer AG in June 2021. Targeted therapeutic and imaging radiopharmaceuticals are being developed by both radiotherapy businesses. It is anticipated that this acquisition would broaden Bayer's current nuclear medicine cancer offering.

Source (https://www.bayer.com/media/en-us/bayer-acquires-noria-and-psma-therapeutics-to-expand-portfolio-in-prostate-cancer/) 

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Nuclear Medicine/Radiopharmaceuticals Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the nuclear medicine/radiopharmaceuticals market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.